Organon

An investment of $10,000 in Organon Company shares on 22 October 2021 would have been worth only $3,855.86 at the close on 21 October 2026, representing a loss of 61.44%. The closing price on 21 October 2026 was $13.75 and the market capitalization was about $3.60 billion. The calculation does not take stock splits or dividend payments into account. » Więcej na finanzen.net

A year ago the Organon Company share closed at $10.24; it most recently traded at $13.79, corresponding to a performance of +34.67%. An investment of $100 a year ago would therefore be worth about $134.67 today. Market capitalization is most recently around $3.61 billion; stock splits and dividends were not taken into account in the calculation. » Więcej na finanzen.net

Five years ago the Organon Company stock closed at $33.69; on 23.09.2026 the price was $13.73. An investment of $1,000 five years ago would be worth about $407.54 today, a decline of 59.25%. Market capitalization is most recently given as $3.59 billion. The calculation does not take stock splits and dividends into account. » Więcej na finanzen.net

Someone who had invested 100 USD in Organon Company three years ago would now own 5.118 shares and the value would be 69.96 USD, representing a loss of 30.04%. The stock's closing price is reported at 13.67 USD, while the price back then was 19.54 USD. Market value most recently at 3.59 billion USD; stock splits and dividends were not taken into account in the calculation. » Więcej na finanzen.net

The FDA has accepted an application seeking to extend the approved duration of use for the hormone-free copper IUD MIUDELLA from three to six years; a decision is expected in the second quarter of 2027. Organon expects commercial availability by the end of 2026 and had licensed worldwide rights to MIUDELLA from Sebela Women’s Health. Phase‑3 data in 1,904 women showed a Pearl index of 0.94 in the first year and 1.05 over three years (effectiveness ~99%); common adverse events were heavier menstrual bleeding, pain and intermenstrual bleeding. The product includes a Risk Evaluation and Mitigation Strategy and requires certification and registration of medical personnel before dispensing and insertion. » Więcej na de.investing.com